Diquafosol Sodium Eye Drops

As a highly selective P2Y₂ agonist eye drop, Diquafosol Pharmaceutical Eye Drops target ocular surface receptors to simultaneously stimulate secretion of aqueous fluid, mucin and lipids, delivering dual effects of endogenous secretion promotion and tear film repair. It features clear efficacy, good local tolerance, long‑lasting dry eye symptom relief and corneal‑conjunctival epithelial repair, with well‑defined pharmacological effects and outstanding safety.

Diquafosol Sodium Eye Drops are widely adaptable to clinical dry eye treatment, ophthalmic procedures and postoperative ocular surface care, supporting outpatient prescription, home medication and long‑term chronic disease management. Sterile sealed packaging and standard storage conditions ensure stable transport and storage, supporting standardized dry eye therapy.

Diquafosol Sodium Ophthalmic Solution establishes a full‑process quality control system covering raw material incoming inspection, formulation production, finished product release, storage and application. Strict internal standards and pharmacopoeia requirements are implemented to ensure product compliance and stability, laying a solid foundation for ophthalmic drug quality.

Production fully complies with global GMP standards and is supported by a complete traceability system for full‑chain batch traceability. Real‑time monitoring of key process parameters and deviation control ensure uniform appearance, accurate content and qualified sterility, with excellent batch‑to‑batch stability.

Supported by high‑standard laboratories, core indicators including appearance, assay, related substances, pH, osmotic pressure and sterility are fully tested. Complete quality documents are issued, and all batches strictly meet pharmacopoeial standards, providing precise and stable quality assurance for clinical dry eye treatment.

A long‑term quality improvement mechanism is established to regularly optimize formulation processes, review quality data and update internal standards in line with regulatory requirements. Closed‑loop management covers production, storage, transportation and after‑sales service to ensure stable quality throughout shelf life and support reliable long‑term supply.

Leading mechanism, root‑cause dry eye improvementHighly selective P2Y₂ receptor activation promotes triple secretion of tears, mucin and lipids, rebuilding stable tear film from the source. Unlike conventional artificial tears, Diquafosol 3% Eye Drops provide dual action of endogenous secretion and ocular surface repair.

Proven clinical efficacy, strong repair capacityRapidly relieves dryness, foreign body sensation, photophobia and fatigue; effectively repairs corneal‑conjunctival epithelial damage, with superior improvement in moderate‑severe and mucin‑deficient dry eye and stable long‑term benefits.

High safety, excellent local tolerancePredominantly local ocular action with minimal systemic absorption; mild and transient adverse reactions, no obvious ocular irritation or long‑term toxicity, suitable for prolonged use.

GMP‑standard production, reliable qualityFull compliance with global GMP standards, strict sterility control, uniform content, stable batches and complete quality documents, meeting international ophthalmic quality requirements.

User‑friendly dosage forms, convenient administrationMulti‑dose and single‑dose packages available with or without preservatives; comfortable and precise dosing, high patient compliance.

Wide application, strong clinical compatibilitySuitable for dry eye treatment, postoperative care, video terminal dry eye and chronic ocular surface damage; compatible for monotherapy or combination use across multiple departments.